

**BAXTER INTERNATIONAL INC.**  
**Net Sales**  
**Periods Ending December 31, 2009 and 2008**  
**(unaudited)**  
**(\$ in millions)**

	Q4 2009	Q4 2008	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2009	YTD 2008	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
United States	\$694	\$647	7%	7%	\$2,662	\$2,401	11%	11%
International	824	712	16%	7%	2,911	2,907	0%	9%
<b>Total</b>	<b>\$1,518</b>	<b>\$1,359</b>	<b>12%</b>	<b>7%</b>	<b>\$5,573</b>	<b>\$5,308</b>	<b>5%</b>	<b>10%</b>
<b>Medication Delivery</b>								
United States	\$615	\$590	4%	4%	\$2,225	\$2,145	4%	4%
International	697	584	19%	10%	2,424	2,415	0%	10%
<b>Total</b>	<b>\$1,312</b>	<b>\$1,174</b>	<b>12%</b>	<b>7%</b>	<b>\$4,649</b>	<b>\$4,560</b>	<b>2%</b>	<b>7%</b>
<b>Renal</b>								
United States	\$100	\$98	2%	2%	\$385	\$388	(1%)	(1%)
International	525	459	14%	7%	1,881	1,918	(2%)	5%
<b>Total</b>	<b>\$625</b>	<b>\$557</b>	<b>12%</b>	<b>6%</b>	<b>\$2,266</b>	<b>\$2,306</b>	<b>(2%)</b>	<b>4%</b>
<b>Baxter excluding Transfusion Therapies</b>								
United States	\$1,409	\$1,335	6%	6%	\$5,272	\$4,934	7%	7%
International	2,046	1,755	17%	8%	7,216	7,240	0%	8%
<b>Total</b>	<b>\$3,455</b>	<b>\$3,090</b>	<b>12%</b>	<b>7%</b>	<b>\$12,488</b>	<b>\$12,174</b>	<b>3%</b>	<b>7%</b>
<b>Transfusion Therapies<sup>1</sup></b>								
United States	\$10	\$17	(41%)	(41%)	\$45	\$110	(59%)	(59%)
International	5	24	(79%)	(79%)	29	64	(55%)	(47%)
<b>Total</b>	<b>\$15</b>	<b>\$41</b>	<b>(63%)</b>	<b>(63%)</b>	<b>\$74</b>	<b>\$174</b>	<b>(57%)</b>	<b>(55%)</b>
<b>Baxter International Inc.</b>								
United States	\$1,419	\$1,352	5%	5%	\$5,317	\$5,044	5%	5%
International	2,051	1,779	15%	7%	7,245	7,304	(1%)	7%
<b>Total</b>	<b>\$3,470</b>	<b>\$3,131</b>	<b>11%</b>	<b>6%</b>	<b>\$12,562</b>	<b>\$12,348</b>	<b>2%</b>	<b>7%</b>

<sup>1</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.